{
    "clinical_study": {
        "@rank": "120985", 
        "arm_group": {
            "arm_group_label": "Autologous transplant  of ADA gene corrected bone marrow", 
            "arm_group_type": "Experimental", 
            "description": "Autologous transplantation of EFS-ADA transduced CD34+ cells from the bone marrow"
        }, 
        "brief_summary": {
            "textblock": "In this current study, the investigators will determine whether using a lentiviral vector\n      (based on HIV-1) will be more effective and safer at gene transfer to hematopoietic stem\n      cells compared to previous gene transfer vectors based on murine (mouse) retroviruses for\n      ADA-deficient SCID.  The level of gene transfer in blood cells and immune function will be\n      measured as endpoints."
        }, 
        "brief_title": "Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Adenosine Deaminase (ADA)-Deficient SCID", 
        "condition_browse": {
            "mesh_term": [
                "Immunologic Deficiency Syndromes", 
                "Severe Combined Immunodeficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be open to ten (10) infants and children diagnosed with ADA-deficient SCID\n      who do not have a medically eligible, HLA-identical sibling donor for bone marrow\n      transplantation. The EFS-ADA lentiviral vector with the human ADA cDNA will be used to\n      transduce autologous CD34+ cells from the bone marrow of these subjects.  The subjects will\n      receive 4 mg/kg busulfan prior to re-infusion of their gene-modified cells.  Safety is the\n      primary endpoint.  During the follow-up phase, the investigators will determine whether the\n      cells can engraft and produce mature cells that contain and express the corrected ADA gene\n      in the absence of PEG-ADA enzyme replacement therapy (ERT), which will be withheld at Day\n      +30 following transplant.  Efficacy studies to evaluate level of immune reconstitution will\n      begin in the first year and will continue in the second year.  This Phase I/II clinical\n      trial will be performed at Mattel Children's Hospital, UCLA and at the Mark O. Hatfield\n      Clinical Research Center, NIH."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Children \u2265 1.0 months of age with a diagnosis of ADA-deficient SCID based on A.\n        Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in\n        cultured fetal cells to levels consistent with ADA-deficient SCID as determined by\n        reference laboratory, AND\n\n        B. Evidence of severe combined immunodeficiency based on either:\n\n          1. Family history of first order relative with ADA deficiency and clinical and\n             laboratory evidence of severe immunologic deficiency, OR\n\n          2. Evidence of severe immunologic deficiency in subject prior to institution of immune\n             restorative therapy, based on\n\n               1. lymphopenia (absolute lymphocyte count <400 cells/mcL) OR absence or low number\n                  of T cells (absolute CD3+ count <300 cells/mcL) OR\n\n               2. severely decreased T lymphocyte blastogenic responses to phytohemagglutinin\n                  (either <10% of lower limit of normal controls for the diagnostic laboratory,\n                  <10% of the response of the normal control of the day, or stimulation index <10)\n\n                    -  Ineligible for matched sibling allogeneic bone marrow transplantation:\n                       absence of a medically eligible HLA-identical sibling, with normal immune\n                       function, who may serve as an allogeneic bone marrow donor\n\n                    -  Signed written informed consent according to guidelines of the IRB (UCLA\n                       Office of Human Research Protection Program and National Human Genome\n                       Research Institute (NHGRI) Institutional Review Board\n\n        Exclusion Criteria:\n\n          1. Age \u2264 1.0 months Appropriate organ function as outlined below must be observed within\n             8 weeks of entering this trial.\n\n          2. Hematologic\n\n               1. Anemia (hemoglobin < 10.5 g/dl at < 2 years of age, or < 11.5 g/dl at > 2 years\n                  of age).\n\n               2. Neutropenia (absolute granulocyte count <500/mm3. If ANC< 1,000, absence of\n                  myelodysplastic syndrome on bone marrow aspirate and biopsy and normal marrow\n                  cytogenetics.\n\n               3. Thrombocytopenia (platelet count < 150,000/mm3, at any age).\n\n               4. PT or PTT > 2X the upper limits of normal (patients with a correctable\n                  deficiency controlled on medication will not be excluded).\n\n               5. Cytogenetic abnormalities on peripheral blood or bone marrow or amniotic fluid\n                  (if available).\n\n          3. Infectious\n\n             a. Evidence of active opportunistic infection or infection with HIV-1, hepatitis B,\n             Hepatitis C, CMV or parvovirus B 19 by DNA PCR within 30-90 days prior to bone marrow\n             harvest.\n\n          4. Pulmonary\n\n               1. Resting O2 saturation by pulse oximetry < 95% on room air.\n\n               2. Chest x-ray indicating active or progressive pulmonary disease.\n\n          5. Cardiac\n\n               1. Abnormal electrocardiogram (EKG) indicating cardiac pathology.\n\n               2. Uncorrected congenital cardiac malformation with clinical symptomatology.\n\n               3. Active cardiac disease, including clinical evidence of congestive heart failure,\n                  cyanosis, hypotension.\n\n               4. Poor cardiac function as evidenced by LV ejection fraction < 40% on\n                  echocardiogram.\n\n          6. Neurologic\n\n               1. Significant neurologic abnormality by examination.\n\n               2. Uncontrolled seizure disorder.\n\n          7. Renal\n\n               1. Renal insufficiency: serum creatinine >= 1.2 mg/dl, or >= 3+ proteinuria.\n\n               2. Abnormal serum sodium, potassium, calcium, magnesium, phosphate at grade III or\n                  IV by Division of AIDS Toxicity Scale.\n\n          8. Hepatic/GI:\n\n               1. Serum transaminases > 5X the upper limit of normal (ULN).\n\n               2. Serum bilirubin > 2X ULN.\n\n               3. Serum glucose >  1.5x ULN.\n\n               4. Intractable severe diarrhea.\n\n          9. Oncologic\n\n               1. Evidence of active malignant disease other than dermatofibrosarcoma protuberans\n                  (DFSP)\n\n               2. Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years\n                  following the infusion of genetically corrected cells\n\n               3. Evidence of DFSP expected to be life limiting within the 5 years following the\n                  infusion of genetically corrected cells\n\n         10. Known sensitivity to Busulfan\n\n         11. General\n\n               1. Expected survival < 6 months.\n\n               2. Pregnant.\n\n               3. Major congenital anomaly.\n\n               4. Ineligible for autologous HSCT by the criteria at the clinical site.\n\n               5. Other conditions which in the opinion of the principal investigator and/or\n                  co-investigators, contra-indicate the bone marrow harvest, the administration of\n                  busulfan, infusion of transduced cells or indicate the patient or patient's\n                  parents/primary caregivers inability to follow protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852071", 
            "org_study_id": "IND 15440", 
            "secondary_id": [
                "U01AI100801", 
                "2P01 HL073104"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Autologous transplant  of ADA gene corrected bone marrow", 
            "description": "Eligible subjects will undergo bone marrow harvest under general anesthesia. The marrow will be processed to isolate CD34+ cells and transduced with the EFS-ADA lentiviral vector.  If sufficient cells are obtained, the subjects will undergo marrow cytoreduction with busulfan (4 mg/kg).  If the transduced CD34+ final cell product meets all release criteria, the cells will be infused intravenously.  PEG-ADA enzyme replacement therapy will be discontinued at day +30.  After discharge from the hospital, the subject will be seen for interval history and examination by either their home physician, the principal investigator or a clinical investigator and have blood drawn at months 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 21, and 24.", 
            "intervention_name": "EFS-ADA transduced CD34+ cells from the bone marrow", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "gene therapy, hematopoietic stem cell, SCID, lentivirus", 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dkohn1@mednet.ucla.edu", 
                    "last_name": "Donald B Kohn, MD", 
                    "phone": "310-794-1964"
                }, 
                "contact_backup": {
                    "email": "kshaw@mednet.ucla.edu", 
                    "last_name": "Kit L Shaw, PhD", 
                    "phone": "(310) 267-0584"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Mattel Children's Hospital, UCLA"
                }, 
                "investigator": [
                    {
                        "last_name": "Satiro de Oliveira, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ami Shah, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Gay M Crooks, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Theodore Moore, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fabio@nhgri.nih.gov", 
                    "last_name": "Fabio Candotti, MD", 
                    "phone": "301-435-2944"
                }, 
                "contact_backup": {
                    "email": "sokolicr@mail.nih.gov", 
                    "last_name": "Robert Sokolic, MD", 
                    "phone": "(301) 451-1498"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "Mark O. Hatfield Clinical Research Center, NIH"
                }, 
                "investigator": [
                    {
                        "last_name": "Fabio Candotti, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Robert Sokolic, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)", 
        "overall_contact": {
            "email": "dkohn1@mednet.ucla.edu", 
            "last_name": "Donald B Kohn, MD", 
            "phone": "(310) 794-1964"
        }, 
        "overall_contact_backup": {
            "email": "kshaw@mednet.ucla.edu", 
            "last_name": "Kit L Shaw, PhD", 
            "phone": "(310) 267-0584"
        }, 
        "overall_official": {
            "affiliation": "University of California, Los Angeles", 
            "last_name": "Donald B Kohn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety will be assessed by recording clinical adverse events.", 
                "measure": "Assess safety by recording clinical toxicities.", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Replication-competent lentivirus exposure will be assessed by Western blot analysis for antibodies to VSV-G protein.", 
                "measure": "Assess safety by determining absence or presence of exposure to replication-competent lentivirus (RCL)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Monoclonal expansion of blood cells by vector-mediated activity will be assessed by nrLAM-PCR", 
                "measure": "Assess safety by evaluating the absence or development of monoclonal expansion or leukoproliferative complications from vector insertional effects", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Overall survival will be assessed", 
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Event-free survival will be assessed by determining the numbers of subjects who remain alive with adequate immune reconstitution and do not need an allogeneic hematopoietic stem cell transplant or re-institution of enzyme replacement therapy.", 
                "measure": "Event-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "reference": {
            "PMID": "22968453", 
            "citation": "Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852071"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Los Angeles", 
            "investigator_full_name": "Donald B. Kohn, M.D.", 
            "investigator_title": "Professor, Depts. of Microbiology, Immunology & Molecular Genetics and Pediatrics", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The frequency of peripheral blood cells containing the EFS-ADA transferred human ADA cDNA will be determined by qPCR as an index of gene transduction and engraftment of hematopoietic stem cells.", 
                "measure": "Determine the frequency of gene marking in peripheral blood cells", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The clonal diversity of vector integration sites will be determined using nrLAM-PCR", 
                "measure": "Quantify clonal diversity of vector integrants", 
                "safety_issue": "No", 
                "time_frame": "2 Years"
            }, 
            {
                "description": "The ADA enzymatic activity in peripheral blood mononuclear cells will be measured by biochemical assay.", 
                "measure": "Quantify ADA enzyme activity in peripheral blood mononuclear cells", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The levels of adenine nucleotides in erythrocytes will be measured by HPLC.", 
                "measure": "Quantify total adenine nucleotides in erythrocytes", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The absolute lymphocyte counts (ALC) on complete blood count will be measured as an index of immune reconstitution.", 
                "measure": "Determine absolute lymphocytes on complete blood count", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The absolute numbers of T, B and NK lymphocytes will be determined using flow cytometry as an index of immune reconstitution", 
                "measure": "Quantify the absolute numbers T, B, and NK lymphocytes", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The proliferative responses of lymphocyte to mitogen stimulation will be quantified as an index of immune reconstitution.", 
                "measure": "Assess lymphocyte mitogenic proliferation", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The levels of immunoglobulin classes (IgG, IgM, IgA) will be quantified as an index of immune reconstitution", 
                "measure": "Measure quantitative immunoglobulins by class", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The development of specific antibody responses to vaccine antigens will be quantified as an index of immune reconstitution", 
                "measure": "Quantify specific antibody responses", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "T lymphocyte reconstitution will be assessed by TCR Vbeta family usage enumeration by flow cytometry and TREC assay", 
                "measure": "Assess T lymphocyte reconstitution", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "University of California, Los Angeles", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Human Genome Research Institute (NHGRI)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Donald B. Kohn, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}